OligoprogressionNCT06918951
Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers
A study testing Stereotactic ablative radiotherapy (SABR) and Palliative radiotherapy in people with Oligoprogression and Oligometastatic Disease, run by British Columbia Cancer Agency at 1 site in Canada.
Trial summary
STOP-2 is a phase III multi-institutional double-blind randomized trial. 194 participants will be enrolled in this trial. Participants will be randomized in a 1:1 ratio between the Control Arm vs. the Experimental Arm. Participants, enrolling oncologists, and the statistician will be blinded to trial arm assignment. Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Oligoprogression, Oligometastatic Disease, OligoProgressive Metastatic Disease
- What is being tested?
- Stereotactic ablative radiotherapy (SABR) and Palliative radiotherapy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 194 participants
- Where
- 1 siteCanada
- Study dates
- 4 Dec 2025to 1 Jun 2033
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 19 or older
- Able to provide informed consent
- Histologically confirmed solid malignancy (excluding lymphoma or myeloma) with metastatic disease detected on imaging
- Biopsy of metastasis at some time prior to enrollment is preferred, but not required
- ECOG performance status 0-2
- Life expectancy ≥ 6 months
Show all 20Show fewer
- Progression meeting RECIST criteria in up to 5 individual lesions. Progression may be defined as:
- Progression of an individual metastasis according to RECIST 1.1 criteria (≥ 20% enlargement of the tumour vs. baseline or nadir, taking as reference the smallest diameter seen prior to starting or during systemic therapy, and associated with a 5 mm minimum increase in size) OR
- Unambiguous development of a new metastatic lesion at least 5 mm in size OR
- Progressive enlargement of a known metastasis on 2 consecutive imaging studies 2-3 months apart with a minimum 5 mm increase in size from baseline.
- A progressing primary tumor is eligible as per the criteria above
- If the participant is on systemic therapy at the time of oligoprogression:
- The most recent systemic therapy agent must have been delivered for a total of at least 3 months, with an initial partial response (PR), complete response (CR) or stable disease (SD) prior to the development of oligoprogressive lesions
- If the participant is not on systemic therapy at the time of oligoprogression:
- (i.e., "oligorecurrence"(1), however, included as "oligoprogression" for the purpose of this study protocol):
- There must be PR, CR or SD persisting for at least 3 months prior to the development of oligoprogressive lesions
- Participants who are not on systemic therapy at the time of oligoprogression must have other site(s) of disease (metastases or primary tumor) that are stable or resolved and have not received definitive treatment (inclusive of surgery, radical doses of radiotherapy including SABR, or ablation) and are not going to receive SABR.
- All sites of oligoprogression can be safely treated
- Restaging completed within 12 weeks prior to randomization (see section 5.1)
- Negative urine pregnancy test for People of Child-Bearing Potential (POCBP) within 4 weeks of radiotherapy start date.
Who cannot join
- Serious medical comorbidities precluding radiotherapy. These include ataxia-telangiectasia or scleroderma, Crohn's disease in participants where the gastrointestinal (GI) tract will receive radiotherapy, or ulcerative colitis where the bowel will receive radiotherapy.
- For participants with oligoprogressive lesions in the lung or thorax, this includes interstitial lung disease.
- Substantial overlap with a previously treated radiation volume. Prior radiotherapy in general is allowed, provided that the composite plan meets dose constraints herein. For participants treated with radiation previously, biological effective dose calculations should be used to equate previous doses to the tolerance doses listed in Appendix 1. A tissue recovery factor may be used in these calculations and if so, must be clearly documented, along with elapsed time from previous radiotherapy, and approved by the local principal investigator.
- Current malignant pleural effusion, malignant ascites, or leptomeningeal disease
- Inability to treat all sites of oligoprogressive disease
- Liver metastases requiring placement of fiducial markers for SABR, as this would compromise successful blinding. Liver metastases are eligible if: 1) they are treated at an institution that offers liver SABR without fiducial markers or 2) pre-existing markers such as surgical clips or calcifications would serve as fiducial markers
Show all 14Show fewer
- Brain metastasis > 3.5 cm in size or a total volume of brain metastases greater than 30 cc.
- Clinical or radiologic evidence of spinal cord compression. Participants can be eligible if surgical resection has been performed.
- Participants with spine instability as judged by a Spinal Instability Neoplastic Score (SINS) of >12.
- Dominant brain metastasis requiring surgical decompression
- For participants with liver metastases; moderate/severe liver dysfunction (Child Pugh B or C)
- Liver metastases located in the "Biliary no fly zone" defined for this trial as common biliary track, cystic duct and distal branches (1 cm) + 5 mm
- Surgical resection of all oligoprogression metastases (i.e. no lesion available to be treated with SABR)
- Pregnant or lactating individuals
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
BC Cancer - Surrey
Surrey, British Columbia, V3V 1Z2
Sarah Baker, MD, PhD, FRCPC, 604-930-4032, sarah.baker1@bccancer.bc.ca
About this study
Official title: Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers: A Double-Blind Randomized Phase III Trial
STOP-2 is a phase III multi-institutional double-blind randomized trial. 194 participants will be enrolled in this trial. Participants will be randomized in a 1:1 ratio between the Control Arm vs. the Experimental Arm.
Participants, enrolling oncologists, and the statistician will be blinded to trial arm assignment.
Read more
In the control arm, radiotherapy will consist of 8 Gy in 1 fraction to all sites of oligoprogression, and the experimental arm will consist of SABR treatment to all sites of oligoprogression.
Primary Objectives
- To assess the impact of SABR, compared to palliative conventional radiotherapy, on Progression-free survival on next line systemic therapy (PFS-NEST), oncologic outcomes, and Quality of Life (QOL) in participants with 1-5 oligoprogressing lesions.
- To assess the feasibility of the clinical trial in terms of accrual and success of double-blinding.
Secondary Objectives
- To evaluate and compare the impact of SABR and palliative radiation therapy on the overall survival (OS), progression free survival (PFS), polymetastatic progression-free survival (PPFS);
- To assess and compare the proportion of participants receiving additional radiation therapy and other metastasis-directed interventions during follow-up between both arms;
- To compare the impact of SABR and palliative radiation therapy on the time to initiation of the next line of systemic therapy;
- To identify and compare the anatomic sites of disease progression between the experimental (SABR) and control (palliative radiation) arms;
- To compare the treatment related toxicity among participants in each arm;
- To evaluate and compare the quality of life among participants in each arm;
- To assess the cost-effectiveness of the experimental arm compared to the control arm.
- Being tested
- Stereotactic ablative radiotherapy (SABR), Palliative radiotherapy
- Keywords
- SABR, Radiotherapy, Quality of life, Metastatic Cancer
- Medical subject headings
- Neoplasm Metastasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Stereotactic ablative radiotherapy (SABR)Radiation
SABR is a safe and effective modality for metastasis-directed therapy, delivering a high dose of radiotherapy to a small target using conformal techniques. Emerging evidence suggests that SABR for oligoprogressive cancer may extend the duration of systemic therapy, and result in improvements in Progression Free Survival (PFS) and Overall Survival (OS) compared to historic controls.
Palliative radiotherapyRadiation
Radiotherapy will consist of 8 Gy in 1 fraction to all sites of oligoprogression.
Participants will continue their current systemic therapy (if already on systemic therapy at the time of oligoprogression event) or continue off systemic therapy (if the participant was not on systemic therapy at the time of the oligorecurrence event).
| Study group | Role | What they receive |
|---|---|---|
| Control Arm (Palliative Radiotherapy) | Active comparator | Not described Receives: Radiation: Palliative radiotherapy |
| Experimental Arm (SABR) | Experimental | Not described Receives: Radiation: Stereotactic ablative radiotherapy (SABR) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression-Free Survival on Next Line Systemic Therapy (PFS-NEST)
Time from randomization to progression (RECIST criteria) beyond next line of systemic therapy or death from any cause or date of last follow-up, whichever occurs first. Next line systemic therapy is the first new systemic therapy initiated after documented disease progression
Measured: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Evaluation of feasibility of the clinical trial in terms of successful accrual
Accrual will be measured by the number of participants enrolled in the trial within the specified time frame.
Measured: 12 and 24 months
Evaluation of feasibility of the clinical trial in terms of success of double-blinding
The success of double-blinding will be measured by providing both the participant and oncologist with a blinding questionnaire asking them to select the suspected trial arm assignment (options include palliative arm, SABR arm, or unknown).
Measured: 6 weeks
Secondary outcomes (10)
Evaluation of OS, PFS, and PPFS
To evaluate and compare the impact of SABR and palliative radiation therapy on the overall survival (OS), progression free survival (PFS), polymetastatic progression-free survival (PPFS);
Measured: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Time to next line systemic therapy
To assess and compare the proportion of participants receiving additional radiation therapy and other metastasis-directed interventions during follow-up between both arms;
Measured: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Comparing the anatomic sites of disease progression
A list of anatomical sites at which there are new or progressing lesions will be collected
Measured: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Evaluation of the treatment related toxicities
Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 5 for each organ treated (e.g., liver, lung, bone)
Measured: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Comparing the quality of life among participants in each arm using Functional Assessment of Cancer Therapy: General (FACT-G)
Quality of life will be assessed with the FACT-G questionnaire. The FACT-G score ranges from 0 to 108, with higher scores indicating a better quality of life.
Measured: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Comparing the quality of life among participants in each arm using EuroQol 5-Dimension 5-Level (EQ-5D-5L)
Quality of life will be assessed with the EQ-5D-5L questionnaire. The EQ-5D-5L index score ranges from -0.224 to 1, with higher scores indicating a better quality of life.
Measured: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Comparing cost-effectiveness of the arms using the resource utilization forms
Costs associated with each treatment arm will be measured using resource utilization forms.
Measured: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Comparing cost-effectiveness of the arms using the EQ-5D-5L
Costs associated with each treatment arm will be measured using EQ-5D-5L
Measured: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Evaluation of Tumor Response Rate (TRR) using RECIST Criteria
Tumor response rate will be assessed using RECIST criteria.
Measured: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Evaluation of Quality of Life (QOL) using European Organization For Research And Treatment Of Cancer (EORTC QLQ-C30) Questionnaire
Health-related quality of life will be measured using the EORTC QLQ-C30 questionnaire, covering physical functioning, emotional functioning, and symptom scales.
This questionnaire consists of 30 items, and the score range is 0-100. On this scale, a higher score indicates a higher (better) level of functioning or a higher (worse) level of symptoms, depending on the type of scale.
Measured: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Apr 2025
- Study start4 Dec 2025
- Primary completion1 Jun 2030 (estimated)
- Study completion1 Jun 2033 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OligoprogressionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study is a phase III, multicenter, double-blind, randomized trial. Participants will be randomized in a 1:1 ratio between conventional palliative radiotherapy (Control Arm; Arm 1) vs. SABR (Experimental Arm; Arm 2) to all sites of oligoprogressing disease.
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 194 participants (estimated)
Sponsor and investigators
- Lead sponsor
- British Columbia Cancer Agency
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06918951
- Sponsor's protocol ID
- STOP-2
- Status last verified
- Dec 2025
- First submitted
- 10 Mar 2025
- Last updated
- 15 Dec 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 15 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers: A Double-Blind Randomized Phase III Trial
- ClinicalTrials.gov ID
- NCT06918951
- Acronym / sponsor ID
- STOP-2
- Keywords
- SABR, Radiotherapy, Quality of life, Metastatic Cancer
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 194 participants (estimated)
- Lead sponsor
- British Columbia Cancer AgencyUniversity, hospital or other
- Study start
- 4 Dec 2025 (actual)
- Primary completion
- 1 Jun 2030 (estimated)
- Study completion
- 1 Jun 2033 (estimated)
- First posted
- 9 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
STOP-2 is a phase III multi-institutional double-blind randomized trial. 194 participants will be enrolled in this trial. Participants will be randomized in a 1:1 ratio between the Control Arm vs. the Experimental Arm.
Participants, enrolling oncologists, and the statistician will be blinded to trial arm assignment.
In the control arm, radiotherapy will consist of 8 Gy in 1 fraction to all sites of oligoprogression, and the experimental arm will consist of SABR treatment to all sites of oligoprogression.
Primary Objectives
- To assess the impact of SABR, compared to palliative conventional radiotherapy, on Progression-free survival on next line systemic therapy (PFS-NEST), oncologic outcomes, and Quality of Life (QOL) in participants with 1-5 oligoprogressing lesions.
- To assess the feasibility of the clinical trial in terms of accrual and success of double-blinding.
Secondary Objectives
- To evaluate and compare the impact of SABR and palliative radiation therapy on the overall survival (OS), progression free survival (PFS), polymetastatic progression-free survival (PPFS);
- To assess and compare the proportion of participants receiving additional radiation therapy and other metastasis-directed interventions during follow-up between both arms;
- To compare the impact of SABR and palliative radiation therapy on the time to initiation of the next line of systemic therapy;
- To identify and compare the anatomic sites of disease progression between the experimental (SABR) and control (palliative radiation) arms;
- To compare the treatment related toxicity among participants in each arm;
- To evaluate and compare the quality of life among participants in each arm;
- To assess the cost-effectiveness of the experimental arm compared to the control arm.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- This study is a phase III, multicenter, double-blind, randomized trial. Participants will be randomized in a 1:1 ratio between conventional palliative radiotherapy (Control Arm; Arm 1) vs. SABR (Experimental Arm; Arm 2) to all sites of oligoprogressing disease.
| Arm | Type | Receives |
|---|---|---|
| Control Arm (Palliative Radiotherapy) | Active comparator | Radiation: Palliative radiotherapy |
| Experimental Arm (SABR) | Experimental | Radiation: Stereotactic ablative radiotherapy (SABR) |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (20 listed)
- Age 19 or older
- Able to provide informed consent
- Histologically confirmed solid malignancy (excluding lymphoma or myeloma) with metastatic disease detected on imaging
- Biopsy of metastasis at some time prior to enrollment is preferred, but not required
- ECOG performance status 0-2
Key exclusion criteria (14 listed)
- Serious medical comorbidities precluding radiotherapy. These include ataxia-telangiectasia or scleroderma, Crohn's disease in participants where the gastrointestinal (GI) tract will receive radiotherapy, or ulcerative colitis where the bowel will receive radiotherapy.
- Substantial overlap with a previously treated radiation volume. Prior radiotherapy in general is allowed, provided that the composite plan meets dose constraints herein. For participants treated with radiation previously, biological effective dose calculations should be used to equate previous doses to the tolerance doses listed in Appendix 1. A tissue recovery factor may be used in these calculations and if so, must be clearly documented, along with elapsed time from previous radiotherapy, and approved by the local principal investigator.
- Current malignant pleural effusion, malignant ascites, or leptomeningeal disease
- Inability to treat all sites of oligoprogressive disease
- Liver metastases requiring placement of fiducial markers for SABR, as this would compromise successful blinding. Liver metastases are eligible if: 1) they are treated at an institution that offers liver SABR without fiducial markers or 2) pre-existing markers such as surgical clips or calcifications would serve as fiducial markers
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Stereotactic ablative radiotherapy (SABR)SABR is a safe and effective modality for metastasis-directed therapy, delivering a high dose of radiotherapy to a small target using conformal techniques. Emerging evidence suggests that SABR for oligoprogressive cancer may extend the duration of systemic therapy, and result in improvements in Progression Free Survival (PFS) and Overall Survival (OS) compared to historic controls. | Radiation | Experimental Arm (SABR) |
| Palliative radiotherapyRadiotherapy will consist of 8 Gy in 1 fraction to all sites of oligoprogression. Participants will continue their current systemic therapy (if already on systemic therapy at the time of oligoprogression event) or continue off systemic therapy (if the participant was not on systemic therapy at the time of the oligorecurrence event). | Radiation | Control Arm (Palliative Radiotherapy) |
Primary outcome
Progression-Free Survival on Next Line Systemic Therapy (PFS-NEST)
Time frame: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Time from randomization to progression (RECIST criteria) beyond next line of systemic therapy or death from any cause or date of last follow-up, whichever occurs first. Next line systemic therapy is the first new systemic therapy initiated after documented disease progression
Evaluation of feasibility of the clinical trial in terms of successful accrual
Time frame: 12 and 24 months
Accrual will be measured by the number of participants enrolled in the trial within the specified time frame.
Evaluation of feasibility of the clinical trial in terms of success of double-blinding
Time frame: 6 weeks
The success of double-blinding will be measured by providing both the participant and oncologist with a blinding questionnaire asking them to select the suspected trial arm assignment (options include palliative arm, SABR arm, or unknown).
10 secondary outcomes
Evaluation of OS, PFS, and PPFS
Time frame: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Time to next line systemic therapy
Time frame: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Comparing the anatomic sites of disease progression
Time frame: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Evaluation of the treatment related toxicities
Time frame: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Comparing the quality of life among participants in each arm using Functional Assessment of Cancer Therapy: General (FACT-G)
Time frame: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Comparing the quality of life among participants in each arm using EuroQol 5-Dimension 5-Level (EQ-5D-5L)
Time frame: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Comparing cost-effectiveness of the arms using the resource utilization forms
Time frame: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Comparing cost-effectiveness of the arms using the EQ-5D-5L
Time frame: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Evaluation of Tumor Response Rate (TRR) using RECIST Criteria
Time frame: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Evaluation of Quality of Life (QOL) using European Organization For Research And Treatment Of Cancer (EORTC QLQ-C30) Questionnaire
Time frame: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Dec 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Oligoprogression
Recruiting
Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression
Oligometastatic Disease, Oligoprogression
Not yet recruitingPhase 2
A Multicenter, Single-Arm, Prospective Phase II Clinical Study of Trastuzumab Rezetecan Combined With Radiotherapy in Patients With HER2-Mutated Oligoprogressive Advanced Non-Small Cell Lung Cancer
HER2-mutated Advanced Non-small Cell Lung Cancer With Oligoprogression
Recruiting
Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.
Brain Metastasis, Oligoprogression
Active, not recruitingPhase 2
Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study
NSCLC, EGFR Positive Non-small Cell Lung Cancer
RecruitingObservational study
SMC Radiation Oncology SABR Cohort for Oligometastasis
Stereotactic Body Radiation Therapy (SBRT), Oligometastasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Stereotactic ablative radiotherapy (SABR) and Palliative radiotherapy in people with Oligoprogression and Oligometastatic Disease, run by British Columbia Cancer Agency at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 20 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sarah Baker, MD, PhD, FRCPC (604-930-4032, sarah.baker1@bccancer.bc.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression-Free Survival on Next Line Systemic Therapy (PFS-NEST) (time frame: 3 months, 6 months, 12 months, 15 months, 18 months, 21 months, 24 months, 36 months, 42 months, 48 months, 54 months, 60 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Dec 2025; AzTrials last refreshed its copy on 26 Oct 2026.